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Inflammation mediated by both innate and adaptive immune cells is necessary for several
important processes during pregnancy. Pro-inflammatory immune cell activation plays a
critical role in embryo implantation, placentation, and parturition; however dysregulation of
these cells can lead to detrimental pregnancy outcomes including spontaneous abortion,
fetal growth restriction, maternal pathology including hypertensive disorders, or fetal and
maternal death. The resolution of inflammation plays an important role throughout preg-
nancy and is largely mediated by immune cells that produce interleukin (IL)-4 and IL-10.
The temporal and spatial aspects of reducing inflammation during pregnancy represent a
complex process that if not functioning optimally can lead to persistent inflammation and
pregnancy complications. In this review, we examine how immune cells that produce IL-4
and IL-10 are regulated throughout pregnancy as well as the effects that reduced IL-4 and
IL-10 signaling has on fetal and maternal physiology.
Keywords: inflammation, pro-inflammatory cytokines, anti-inflammatory cytokines, pregnancy disorders,
immune cells
INTRODUCTION
The immunological features of normal pregnancy are unique as
the maternal immune system has to accept a semi-allogeneic fetus,
a product of two histo-incompatible individuals. Medawar pro-
posed that in order to accept a half-foreign fetus, the mother needs
to be in an immunosuppressed state (1). Recent progress in our
understanding suggests that the maternal immune system not only
needs to be suppressed but at the same time also needs to protect
the mother and the growing fetus from infection during preg-
nancy. Thus, a successful pregnancy depends on the ability of the
mother’s immune system to become tolerant to paternal antigens
as well as the ability to reject the fetus in case of pathogen infection.
The maternal immune response is regulated by a complex array
of cytokines to protect the conceptus and promote proper growth
and development of the placenta. Wegmann and colleagues sug-
gested that during pregnancy there is a T-helper (Th) 2 bias to
promote tolerance to the half-foreign fetus and Th1 cytokines are
detrimental to the tolerance of the conceptus, similar to allografts
in transplant recipients (2–5). It has been found that during toler-
ance induction to an allograft there is a decrease in Th1 cytokines
such as interleukin (IL)-2 and IFNγ and an increase in Th2
cytokines including IL-4 and IL-10. Conversely, high levels of IL-2
and IFNγ were detected in rejecting allografts (6–8). Existing data
suggest that Th2 bias in pregnancy is an oversimplified model and
that during the various stages of pregnancy the pro-inflammatory
and anti-inflammatory cytokine milieu is dynamically modulated.
The first stage of pregnancy, which involves a blastocyst implant-
ing into the uterus, is a predominantly pro-inflammatory phase.
Localized activation of inflammatory mediators occurs and the
mother’s immune system repairs the damage done by the invading
blastocyst. The second phase of pregnancy is a predominantly
anti-inflammatory phase. Th2 cytokine skewing during the second
phase of pregnancy can be systemic or local at the feto-maternal
interface. The last phase of pregnancy is parturition, which causes
contraction of the uterus and again, the pro-inflammatory milieu
is predominant. Inflammation is tightly controlled during all
stages of pregnancy, however excessive and persistent maternal
inflammatory responses are associated with adverse pregnancy
outcomes.
Pregnancy disorders such as preterm birth (PTB), fetal growth
restriction (FGR), and preeclampsia (PE) are often associated
with infection during pregnancy (9–11). Infection due to bacte-
ria, viruses, and parasites, which normally induce a Th1 immune
response can impact placental development and function and ulti-
mately fetal survival (12). Th1 responses induce IFNγ that in
turn propagates Th1 responses by up-regulating IL-12 receptor
expression and inhibiting Th2 responses.
Preterm birth is associated with increased production of pro-
inflammatory cytokines and chemokines such as IL-1β, IL-6,
TNFα, and CXCL8 (13). These cytokines induce prostaglandin
synthesis in the placental tissues that triggers preterm labor (14,
15). Likewise, maternal inflammation due to infection is an impor-
tant contributor to the development of FGR (16). Administra-
tion of the anti-inflammatory cytokine IL-10 can attenuate FGR
induced in rats by lipopolysaccharide (LPS) or infection with E. coli
(17). The addition of exogenous IL-10 reduces fetal resorption in
pregnancies of CBA/J×DBA/2 mice. Anti-IL-10 neutralizing anti-
bodies increase fetal loss and lead to growth defects after birth (18,
19). PE is also associated with an exaggerated maternal inflamma-
tory response. Zenclussen and colleagues demonstrated that adop-
tive transfer of the Th1 cells into pregnant mice was associated with
the development of PE-like symptoms (20). Pro-inflammatory
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cytokines are not only increased in PE but the production of the
anti-inflammatory cytokines IL-4 and IL-10 are also known to be
decreased. In this review, we highlight how immune cells that pro-
duce IL-4 and IL-10 are modulated during pregnancy and their
role in adverse pregnancy outcomes.
IMMUNE CELLS THAT PRODUCE IL-4 AND IL-10 AND THEIR
ACTIONS
Interleukin-4 and IL-10 are pleiotropic anti-inflammatory
cytokines that function mainly by suppressing the pro-
inflammatory milieu. Several different immune cells that produce
IL-4 are activated T cells, mast cells, basophils, eosinophils, and
NKT cells (21, 22). IL-4 aids in the polarization of antigen-
stimulated naïve Th cells into Th2 effector cells as well as propa-
gates Th2 responses by binding to its receptor, IL-4Rα, and acti-
vating the signal transducer and activator of transcription (STAT)
six signaling pathway (23–26). STAT6, through the induction of a
zinc-finger transcription factor GATA3 (GATA-binding protein 3),
might directly suppress Th1 cell development by silencing IFNγ
expression (27). Recent studies also indicate that IL-4 enhances
Th2 immunity by inhibiting Th1 responses through the repression
of IL-12 signaling (28). Several studies implicate a role for IL-4 in
regulatory T cell (Treg) development and maintenance IL-4 sig-
naling through STAT6 is important for FoxP3 mRNA expression
and protein production in natural Tregs (29–32). IL-4 also induces
the formation of inducible Tregs from naïve CD4+ T cells. Thus,
IL-4 not only mediates Th2 cell function but also plays a part in
the regulation of Tregs which play an important role in successful
pregnancies.
Interleukin-10 production was first determined in Th2 cells
and was initially thought to be only produced by immune cells,
but later studies demonstrated that IL-10 is also produced by
non-immune cells (33). Immune cells that produce IL-10 include
subsets of T cells such as Th1, Th2, and Th17, as well as mono-
cytes, macrophages, dendritic cells, human B cells, granulocytes,
eosinophils, and mast cells. Non-immune cells that produce IL-
10 include keratinocytes, epithelial cells, and tumor cells. IL-10
primarily exerts its anti-inflammatory effect by inhibiting pro-
inflammatory cytokines such as IL-1, IL-6, IL-12, and TNF as well
as chemokines (34). IL-10 also inhibits antigen presentation by
blocking MHC class II expression and co-stimulatory molecules
such as CD80 and CD86 (35). IL-10 exerts its biological effect by
binding to its receptor which is composed of two subunits, IL-
10R1 and IL-10R2 (35). Initially, IL-10 binds its cognate receptor
IL-10R1 and the binding of IL-10R2 is specific to initiate a sig-
naling cascade. IL-10 then activates Janus kinase (JAK) and STAT
pathways. This recruits Tyk2 and Jak1 to the receptor complex
and induces phosphorylation of the receptors leading to tran-
scription of IL-10-regulated genes (36). IL-10 production is also
associated with other types of immune cells such as macrophages
and myeloid-derived suppressor cells (MDSCs). Following Toll-
like receptor (TLR) activation in macrophages and MDSCs, the
signaling cascade comprising the adaptor molecule TIR-domain-
containing adaptor protein inducing IFNβ (TRIF) is activated. The
extracellular signal-regulated kinase 1 (ERK1), ERK2, p38, and
nuclear factor-κB (NF-κB) pathways are activated leading to the
production of IL-10 and several other genes. IL-10 up-regulates
its own production by modulating tumor progression locus 2
(TPL2) expression (34). Both IL-4 and IL-10 mediate signaling
between immune cells and also regulate recruitment, activation,
and suppression of both immune and non-immune cells.
MODULATION OF IL-4 AND IL-10 DURING PREGNANCY
Anti-inflammatory cytokines perform a multitude of functions
during normal pregnancy by promoting placental formation,
modulating trophoblast invasion and differentiation, inducing
placental proliferation and angiogenesis, and inhibiting pro-
inflammatory cytokines. IL-4 is detectable at the feto–maternal
interface during all phases of pregnancy (37). IL-4 is produced
not only by immune cells of the placenta but also by the maternal
decidua, amniochorionic membranes, cytotrophoblasts, and both
maternal and fetal endothelial cells (38, 39). IL-4 production is
increased in the gravid state and levels of IL-4 increase throughout
normal pregnancy (40). Progesterone is a known inducer of IL-4
and together they act to inhibit Th1 responses during pregnancy.
Given the important role of IL-4 in suppressing inflammation, it is
surprising that IL-4-knockout mice have normal pregnancies with
respect to fetal growth and development (41). This would suggest
that the role of an individual cytokine may not be crucial to the
success of pregnancy but rather depends on the complex interplay
with other cytokines in a spatiotemporal manner.
Interleukin-10 has been shown to be constitutively expressed in
placental villous trophoblasts but not in extravillous trophoblasts
(42). Additionally, uterine NK cells (uNK cells), monocytes, and
Tregs in the decidua are also important producers of IL-10 (36).
IL-10 acts on its receptors (IL-10R) that are expressed on several
cell types including placental trophoblasts, decidual stromal cells,
macrophages, and uNK cells. In mice, IL-10 is expressed through-
out pregnancy and peaks at gestational day 12 (37). To determine
the exact role of IL-10 in pregnancy, pregnant IL-10−/− mice were
compared to pregnant wild type (WT) mice and no change in
litter size or development were noted indicating that IL-10 is not
essential for pregnancy (41). However, IL-10 plays a role in pla-
cental growth and remodeling because IL-10−/− mice exhibited
increases in placental size and maternal blood sinuses (43). IL-10
is not essential for the growth and development of the fetus in mice
but rather it plays an important role to inhibit excessive inflam-
mation. Pregnant IL-10−/− mice are susceptible to low doses of
LPS and CpG (a TLR 9 agonist) compared to WT mice (44, 45).
These results suggest that IL-10 acts as a protective agent dur-
ing infection and deficiency of IL-10 exacerbates inflammation in
mice. Normal pregnant women were determined to have increased
IL-10 production during the first and second trimesters but not
in the third trimester (46). Moreover, IL-10 production decreases
prior to labor and delivery of the fetus and placenta and increases
post labor (47). Precise regulation of IL-4 and IL-10 are important
to curtail maternal inflammation and allow crosstalk between the
placental decidua and the invading fetal trophoblasts at different
stages of pregnancy.
IL-4 AND IL-10 IN SPONTANEOUS ABORTION AND FETAL
GROWTH RESTRICTION
It has been well documented that the lack of fetal tolerance is
largely mediated by Th1 cells. Their recruitment from the maternal
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circulation into the feto–maternal interface and their production
of pro-inflammatory cytokines coupled with a decrease or lack of
increase in anti-inflammatory cytokines can lead to a spectrum
of pregnancy disorders (Figure 1). Various cells that produce IL-
4 and IL-10 including NK cells, T cells, regulatory B cells, and
others are dysregulated and fail to increase production of these
anti-inflammatory cytokines at the appropriate time and location.
Immunological models of spontaneous abortion and FGR in
animals include the female CBA/J×male DBA/2J mating with and
without stress, excessive TLR activation in early pregnancy (LPS
and poly I:C), and transvaginal rIL-17 administration, and all of
these are associated with decreased production of IL-4 and IL-10.
Several studies have reported that abortion-prone CBA/J females
demonstrate decreased circulating and placental levels of IL-4 and
IL-10 (18, 48–52) and that experimental therapeutics at various
time points including a B7 monoclonal antibody, adenoviral-
mediated heme oxygenase-1 overexpression, progesterone or its
derivatives, adoptive transfer of Tregs, or alloimmunization, all
decrease abortion rate and this is associated with increased IL-4
and IL-10 and/or Th2/Th1 ratios (18, 48–50, 52–55). A more direct
study demonstrated that administration of IL-4 as well as IL-4 and
IL-10 decreased the resorption rate in these mice (51). In animals,
TLR activation in early pregnancy induces spontaneous abortion
or resorption and this is regulated by IL-10 as rIL-10 administra-
tion was able to prevent these effects (18, 56–59). Further support
for IL-10 and its role in preventing spontaneous abortion was
demonstrated in mice administered rIL-17 transvaginally on ges-
tational day 1 which decreased decidual IL-10 levels and induced
abortion (53). Adoptive transfer of IL-10-producing Tregs from
pregnant mice increased IL-10 levels and decreased abortion rates
in these mice (53).
These experimental studies are supported by clinical observa-
tions in women who have had recurrent or initial reproductive
failures. Production of IL-4 and IL-10 by NK cells, regulatory B
cells, T cells, and others is decreased in women who have had
spontaneous abortions, recurrent miscarriages, small for gesta-
tional age babies, and infertility. Several studies have reported low
levels of IL-4, IL-4-producing cells, and Th1 cytokine/IL-4 ratios
in women with spontaneous abortions (60–65). With respect to
IL-10, numerous studies have reported low levels of IL-10, IL-10-
producing cells, and Th1 cytokine/IL-10 ratios in women with
spontaneous abortions (40, 61–71). Additionally, women expe-
riencing multiple unsuccessful in vitro fertilization cycles have
increased TNFα+/IL-4+ and TNFα+/IL-10+ T cell ratios (65). A
recent study found that low levels of circulating anti-inflammatory
cytokines during early gestation were associated with habitual mis-
carriages in women (72). Further support for an important role
of IL-4 and IL-10 in preventing reproductive failure was provided
by a study in which i.v. Ig therapy in women with recurrent spon-
taneous abortions increased IL-4 and IL-10 levels and decreased
the ratio of IFNγ+/IL-4+ T cells (73). Together these data sup-
port the notion that a lack of early, appropriate anti-inflammatory
responses and excessive inflammation can lead to reproductive
failure. Further experimental and clinical studies in which aug-
mentation of IL-4- and IL-10-producing immune cells would
determine whether this would be sufficient to induce successful
pregnancies.
FIGURE 1 | Role of IL-4 and IL-10 in pregnancy disorders. Decreased
levels of IL-4 and IL-10 promote persistent inflammation and depending on
the levels, stage of pregnancy, and systemic vs. local effects, can lead to a
spectrum of gestational complications.
IL-4 AND IL-10 IN PREECLAMPSIA
One of the characteristics and potential cause in some cases of PE is
uncontrolled amplification of the maternal immune system. The
excessive pro-inflammatory state seen in PE may be partly due
to increased production of pro-inflammatory cytokines and/or
decreased production of anti-inflammatory cytokines. Indeed,
PE-like symptoms develop in rats following infusion of IL-6 or
TNFα indicating that pro-inflammatory cytokines contribute to
the development of PE (74, 75). Recent experiments from our lab
indicate a pathogenetic role of decreases in the anti-inflammatory
cytokine IL-4 in PE. We demonstrated that although fetal growth
and development was not affected in IL-4−/− mice, mild PE-like
symptoms such as hypertension and proteinuria developed dur-
ing pregnancy. Additionally, deficiency of IL-4 induced systemic
and placental inflammation in mice. These experiments impli-
cate that deficiency of IL-4 contributes to mild cardiovascular and
renal effects and the protective role of IL-4 is more pronounced
during infection. In support, we demonstrated that pregnant IL-
4−/− mice exhibited even further increases in inflammation and
PE-like symptoms following viral mimetic activation of TLR3.
Importantly, non-pregnant IL-4−/− mice did not exhibit hyper-
tension and proteinuria at baseline or following TLR3 activation
(76). These observations also correlate well with numerous clin-
ical studies in which women with PE have been reported to have
decreased IL-4 levels and increased circulating levels of the solu-
ble IL-4 receptor compared with normotensive pregnant women
(77–79). These studies establish a role for decreased IL-4 in the
development of PE and also indicate that administration of IL-4
may be a viable treatment option for women with PE.
Similar to IL-4, several studies document the importance of
IL-10 in preventing PE. Serum from PE patients induces the clin-
ical features of PE such as hypertension, proteinuria, and FGR in
IL-10−/− mice. PE serum induced HIF-1α in the placenta which
may have triggered production of the anti-angiogenic factors sFlt-
1 and sEng and also induced renal pathology and poor spiral
artery remodeling. Endovascular capillary tube formation is also
significantly disrupted by serum from PE patients in these IL-
10−/−mice. However, serum from healthy women or women with
PE administered to non-pregnant animals failed to induce any
PE-like features (80). In another study by Lai et al. deficiency
of IL-10 coupled with hypoxia induced severe PE-like features
including renal pathology, proteinuria, and hypertension. More-
over, increased expression of anti-angiogenic factors, apoptotic
pathways, and placental injury were noted. Expectedly, recombi-
nant IL-10 administration reversed the hypoxia-induced features
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in pregnant IL-10−/− mice confirming the protective role of IL-10
in PE (81). In our studies, pregnant IL-10−/− mice exhibit mild
hypertension, endothelial dysfunction, and proteinuria only dur-
ing pregnancy. In addition, PE-like symptoms were augmented
in IL-10−/− mice following activation of TLR3 during pregnancy
(82). Clinical studies further support reduced production of IL-10
from patients with PE (83).
Based on the aforementioned studies, we hypothesized that
administration of either of the anti-inflammatory cytokines IL-
4 or IL-10 or co-treatment with both recombinant IL-4 and
IL-10 may improve outcomes in TLR-activated PE mice. Adminis-
tration of IL-4, IL-10 alone, or IL-4/IL-10 co-treatment during
gestation normalized blood pressure and endothelial function
in mice treated with a TLR3 agonist. IL-4/IL-10 co-treatment
had the most beneficial effect on fetal development and renal
function as well as decreased the levels of the pro-inflammatory
cytokines IL-6, IFNγ, and TNFα (84). These studies raise the pos-
sibility of using anti-inflammatory cytokines in combination as a
therapeutic option for women with PE.
CONCLUSION
The role of inflammation is important and necessary for successful
pregnancies, however aberrant and persistent inflammation and
the lack of resolution by anti-inflammatory cytokine-producing
cells can lead to a variety of pregnancy disorders depending on
various factors (Figure 1). IL-4 and IL-10 play crucial roles in
the success of pregnancy and there is strong evidence that a defi-
ciency in IL-4 and/or IL-10 contributes to infertility, spontaneous
abortion, PTB, FGR, and hypertensive disorders of pregnancy.
Most studies to date have aimed to determine the role of each
individual cytokine which has generated important findings and
improved our understanding of the role of anti-inflammatory
mediators during pregnancy; however there is considerable redun-
dancy among cytokines and within an immune response. Inte-
grative studies that take into context the local environment and
cytokine milieu, especially during the gravid state, are neces-
sary to determine how cytokine–cell and cell–cell communication
influences local and systemic inflammation and the physiolog-
ical effects during pregnancy. Novel therapies that target the
augmentation of multiple anti-inflammatory cytokines including
both IL-4 and IL-10 may elicit better effects than a single anti-
inflammatory cytokine targeting therapy. The challenge will be in
determining when, where, and how to achieve this during gestation
in order to produce a healthy, successful pregnancy.
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